Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma

Nakashiro,Koh-Ichi; Tanaka,Hiroshi; Goda,Hiroyuki; Iwamoto,Kazuki; Tokuzen,Norihiko; Hara,Shingo; Onodera,Jun; Fujimoto,Ichiro; Hino,Satoshi; Hamakawa,Hiroyuki

doi:10.3892/ijo.2015.3134

Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma

Authors:
- Koh-Ichi Nakashiro
- Hiroshi Tanaka
- Hiroyuki Goda
- Kazuki Iwamoto
- Norihiko Tokuzen
- Shingo Hara
- Jun Onodera
- Ichiro Fujimoto
- Satoshi Hino
- Hiroyuki Hamakawa
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, Department of Oral and Maxillofacial Surgery, Kochi Health Sciences Center, Kochi, Kochi, Japan, Koken Research Institute, Koken Co., Ltd., Tokyo, Japan
Published online on: August 25, 2015 https://doi.org/10.3892/ijo.2015.3134
Pages: 1273-1281

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oncogene addiction can provide therapeutic opportunities in human malignancies. In this study, we aimed to identify critical oncogenes for oral squamous cell carcinoma (OSCC) development and progression. We determined gene expression profiles in 10 primary OSCCs and 10 human OSCC cell lines using Applied Biosystems Human Genome Survey Arrays. Akt1 was the only gene identified that was expressed in all OSCC tissues and cultured cells, but not in non-neoplastic tissues and cells. Subsequently, western blot analysis showed that Akt1 protein was overexpressed in OSCC tissues and cell lines. Immunohistochemistry also showed Akt1 protein expression in 59 of 63 (94%) primary OSCCs. To clarify the oncogenic function of Akt1 in human OSCC cells, we used RNA interference. We designed and synthesized 5 small interfering RNAs specific for Akt1 (siAkt1). Transfecting human OSCC cells with siAkt1 in vitro markedly suppressed their expression of Akt1 protein and significantly reduced their growth rate. Furthermore, the growth of human OSCC tumors which had been subcutaneously xenografted in athymic nude mice lacking interferon responses was markedly inhibited by atelocollagen-mediated systemic siAkt1 administration. We also found that synthetic siAkt1 had an inhibitory effect on the growth of primary cultured OSCC cells. Finally, we investigated the molecular mechanisms involved in the growth inhibitory effect of Akt1 suppression using microarray analysis of human OSCC cells transfected with siAkt1. Knockdown of Akt1 induced the expression of CDKN2B, a tumor suppressor gene, and reduced the expression of TGFBR1, which supports malignant phenotypes. These results suggest that Akt1 functions as a critical oncogene in human OSCC cells and may therefore be an appropriate target for novel OSCC therapies.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Gupta S, Kong W, Peng Y, Miao Q and Mackillop WJ: Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
3	Weinstein IB, Joe A and Felsher D: Oncogene addiction. Cancer Res. 68:3077–3080. 2008. View Article : Google Scholar : PubMed/NCBI
4	Huang SF, Cheng SD, Chien HT, Liao CT, Chen IH, Wang HM, Chuang WY, Wang CY and Hsieh LL: Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncol. 48:67–72. 2012. View Article : Google Scholar
5	Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
6	Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
7	Shintani S, Mihara M, Nakahara Y, Aida T, Tachikawa T and Hamakawa H: Lymph node metastasis of oral cancer visualized in live tissue by green fluorescent protein expression. Oral Oncol. 38:664–669. 2002. View Article : Google Scholar : PubMed/NCBI
8	Klosek SK, Nakashiro K, Hara S, Goda H and Hamakawa H: Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma. Oncol Rep. 20:873–878. 2008.PubMed/NCBI
9	Shintani S, Hamakawa H, Nakashiro K, Shirota T, Hatori M, Tanaka M, Kuroshita Y and Kurokawa Y: Friend leukaemia insertion (Fli)-1 is a prediction marker candidate for radiotherapy resistant oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 39:1115–1119. 2010. View Article : Google Scholar : PubMed/NCBI
10	Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K and Takei Y: Systemic delivery of siRNA specific to tumor mediated by atelocollagen: Combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer. 125:2978–2990. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ochiya T, Takahama Y, Nagahara S, Sumita Y, Hisada A, Itoh H, Nagai Y and Terada M: New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: The Minipellet. Nat Med. 5:707–710. 1999. View Article : Google Scholar : PubMed/NCBI
12	Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, Honma K, Nagahara S, Hanai K, Sano A, et al: Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32:e1092004. View Article : Google Scholar : PubMed/NCBI
13	Azuma K, Nakashiro K, Sasaki T, Goda H, Onodera J, Tanji N, Yokoyama M and Hamakawa H: Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. Biochem Biophys Res Commun. 391:1075–1079. 2010. View Article : Google Scholar
14	Sasaki T, Nakashiro K, Tanaka H, Azuma K, Goda H, Hara S, Onodera J, Fujimoto I, Tanji N, Yokoyama M, et al: Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 399:79–83. 2010. View Article : Google Scholar : PubMed/NCBI
15	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
16	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
17	Lim J, Kim JH, Paeng JY, Kim MJ, Hong SD, Lee JI and Hong SP: Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol. 58:1199–1205. 2005. View Article : Google Scholar : PubMed/NCBI
18	Beck JT, Ismail A and Tolomeo C: Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 40:980–989. 2014. View Article : Google Scholar : PubMed/NCBI
19	Gonzalez E and McGraw TE: The Akt kinases: Isoform specificity in metabolism and cancer. Cell Cycle. 8:2502–2508. 2009. View Article : Google Scholar : PubMed/NCBI
20	Lui VWY, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, et al: Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3:761–769. 2013. View Article : Google Scholar : PubMed/NCBI
21	Cohen Y, Goldenberg-Cohen N, Shalmon B, Shani T, Oren S, Amariglio N, Dratviman-Storobinsky O, Shnaiderman-Shapiro A, Yahalom R, Kaplan I, et al: Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Oral Oncol. 47:946–950. 2011. View Article : Google Scholar : PubMed/NCBI
22	Naruse T, Yanamoto S, Yamada S, Rokutanda S, Kawakita A, Kawasaki G and Umeda M: Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma. Pathol Oncol Res. 21:765–773. 2015. View Article : Google Scholar : PubMed/NCBI
23	Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, et al: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA. 102:12177–12182. 2005. View Article : Google Scholar : PubMed/NCBI